Skip to content


  • Poster presentation
  • Open Access

Tolerogenic dendritic cells in experimental autoimmune encephalomyelitis, specific tolerance induction?

  • 1, 2, 4,
  • 2,
  • 2,
  • 3, 4 and
  • 1, 4
Journal of Translational Medicine201210 (Suppl 3) :P27

  • Published:


  • Multiple Sclerosis
  • Experimental Autoimmune Encephalomyelitis
  • Pertussis
  • Encephalomyelitis
  • Pertussis Toxin


Specific cell therapy with tolerogenic Dendritic Cells (tolDCs) loaded with autoantigens is a promising tool for the attenuation of pathogenic T cells in autoimmune diseases such as Multiple Sclerosis (MS).

The aim of this study was to analyse the in vitro effect of tolerogenic bone marrow derived DCs (BM-DCs) loaded with Myelin Oligodendrocyte Glycoprotein (MOG)40-55 peptide from C57BL/6 mice, on the specific proliferation of splenocytes of mice with EAE.


Chronic EAE was induced in C57BL/6 mice by s.c. immunization with MOG40-55 emulsified in complete Freund's adjuvant. Pertussis Toxin was injected i.v. at days 0 and 2 post-immunization to increase blood-brain-barrier permeability. Clinical score was daily measured based on tail/leg paralysis.

TolBM-DCs were in vitro differenciated with GM-CSF in the presence of vitamin D3 (VD3) for 8 days.

On day 7, maturation was induced with LPS. Viability, efficiency of differentiation and phenotype of tolBM-DCs were evaluated. To assess antigen specificity, tolBM-DCs were pulsed with MOG40-55, after the maturation stimulus (day 7) for 18h and cocultured with syngeneic splenocytes from mice with established EAE.


TolBM-DCs displayed a semi-mature phenotype, exhibited by low levels of MHC class II and coestimulatory molecules (CD40, CD86) compared to control mature BM-DCs (mBM-DCs) differenciated in the absence of VD3. MOG40-55 loaded TolDCs showed to be poor stimulators of specific T cells of mice with EAE, compared to mBM-DCs.


These results suggest that MOG-loaded TolDCs may be a powerful tool to induce specific T-cell hyporesponsiveness in mice with chronic MOG-induced EAE. Hence, treatment with tolDCs loaded with myelin peptides might be a potential therapy for EAE/MS.

Authors’ Affiliations

Immunobiology Laboratory For Research And Diagnostic Applications (LIRAD-BST), Badalona, Spain
Multiple Sclerosis Unit, Dept. of Neurosciences, Germans Trias i Pujol University Hospital (HUGTiP) and Health Science Research Institute (IGTP), Badalona, Spain
Dept. of Immunology, Hospital Vall d’Hebron, Barcelona, Spain
Universitat Autònoma Barcelona, (UAB), Spain